Postes actifs de Karl Richard Gibson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Ixchelsis Ltd.
 Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Directeur Technique/Scientifique/R&D | 27/07/2011 | - |
| Fondateur | 27/07/2011 | - | |
| Sandexis LLP | Fondateur | - | - |
Historique de carrière de Karl Richard Gibson
Formation de Karl Richard Gibson
| University of Cambridge | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 4 |
Opérationnelle
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
| Sandexis LLP |
- Bourse
- Insiders
- Karl Richard Gibson
- Expérience
